Cellular and molecular targets of extracellular vesicles from mesenchymal stem-stromal cells in rheumatoid arthritis
dc.centro | Universidad Cardenal Herrera-CEU | |
dc.contributor.author | Alcaraz Tormo, María José | |
dc.contributor.author | Guillén Salazar, Isabel | |
dc.contributor.other | Producción Científica UCH 2022 | |
dc.contributor.other | UCH. Departamento de Farmacia | |
dc.date | 2022 | |
dc.date.accessioned | 2023-06-16T04:00:18Z | |
dc.date.available | 2023-06-16T04:00:18Z | |
dc.date.issued | 2022-12-16 | |
dc.description | Este artículo se encuentra disponible en la siguiente URL: https://academic.oup.com/stcltm/article/11/12/1177/6786226 | |
dc.description.abstract | Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes progressive joint destruction. Despite the advances in the treatment of this condition there remains a clinical need for safe therapies leading to clinical remission. Mesenchymal stem/stromal cells (MSCs) play immunomodulatory and regenerative roles which can be partly mediated by their secretome. In recent years, the important contribution of extracellular vesicles (EVs) to MSC actions has received an increasing interest as a new therapeutic approach. We provide an extensive overview of the immunomodulatory properties of MSC EVs and their effects on articular cells such as fibroblast-like synoviocytes that play a central role in joint destruction. This review discusses the anti-arthritic effects of MSC EVs in vitro and in animal models of RA as well as their potential mechanisms. Recent preclinical data suggest that transfer of non-coding RNAs by MSC EVs regulates key signaling pathways involved in the pathogenesis of RA. We also examine a number of EV modifications for improving their anti-arthritic efficacy and carrier ability for drug delivery. | |
dc.format | application/pdf | |
dc.identifier.citation | Alcaraz, M. J. & Guillén, M. I. (2022). Cellular and molecular targets of extracellular vesicles from mesenchymal stem/stromal cells in rheumatoid arthritis. Stem Cells Translational Medicine, vol. 11, i. 12 (dec.), pp. 1177–1185. DOI: https://doi.org/10.1093/stcltm/szac075 | |
dc.identifier.doi | https://doi.org/10.1093/stcltm/szac075 | |
dc.identifier.issn | 2157-6564 | |
dc.identifier.issn | 2157-6580 (Electrónico) | |
dc.identifier.uri | http://hdl.handle.net/10637/14443 | |
dc.language | es | |
dc.language.iso | en | |
dc.publisher | Oxford University | |
dc.relation | Este artículo de investigación ha sido financiado por una beca del Ministerio de Ciencia, Innovación y Universidades del Gobierno de España y el FEDER (SAF2017-85806-R). | |
dc.relation | UCH. Financiación Nacional | |
dc.relation.ispartof | Stem Cells Translational Medicine, vol. 11, i. 12 (dec. 2022) | |
dc.relation.projectID | SAF2017-85806-R | |
dc.rights | open access | |
dc.rights.cc | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Rheumatoid arthritis - Treatment. | |
dc.subject | Células madre - Uso terapéutico. | |
dc.subject | Artritis reumatoide - Tratamiento. | |
dc.subject | Enfermedades autoinmunes - Tratamiento. | |
dc.subject | Autoimmune diseases - Treatment. | |
dc.subject | Stem cells - Therapeutic use. | |
dc.title | Cellular and molecular targets of extracellular vesicles from mesenchymal stem-stromal cells in rheumatoid arthritis | |
dc.type | Artículo | |
dspace.entity.type | Publication | es |
relation.isAuthorOfPublication | c4376958-fc57-4066-a49d-6bbcadd31085 | |
relation.isAuthorOfPublication.latestForDiscovery | c4376958-fc57-4066-a49d-6bbcadd31085 |
Files
Original bundle
1 - 1 of 1